Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,510.10 | 10.10 | -0.12% |
| CAC 40 | 7,836.79 | 37.04 | -0.47% |
| DAX 40 | 23,527.01 | 111.55 | -0.47% |
| Dow JONES (US) | 42,051.06 | 89.37 | -0.21% |
| FTSE 100 | 8,585.01 | 17.91 | -0.21% |
| HKSE | 23,679.17 | 38.52 | 0.16% |
| NASDAQ | 19,146.81 | 136.72 | 0.72% |
| Nikkei 225 | 37,704.10 | 424.03 | -1.11% |
| NZX 50 Index | 12,812.08 | 32.82 | 0.26% |
| S&P 500 | 5,892.58 | 6.03 | 0.10% |
| S&P/ASX 200 | 8,277.20 | 2.40 | -0.03% |
| SSE Composite Index | 3,393.47 | 10.47 | -0.31% |